Adit Ben-Baruch

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2041069/publications.pdf

Version: 2024-02-01

55 papers	4,921 citations	136950 32 h-index	155660 55 g-index
57 all docs	57 docs citations	57 times ranked	7115 citing authors

#	Article	IF	Citations
1	International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors. Pharmacological Reviews, 2014, 66, 1-79.	16.0	735
2	The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Letters, 2008, 267, 271-285.	7.2	502
3	A Possible Role for CXCR4 and Its Ligand, the CXC Chemokine Stromal Cell-Derived Factor-1, in the Development of Bone Marrow Metastases in Neuroblastoma. Journal of Immunology, 2001, 167, 4747-4757.	0.8	370
4	The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Research, 2002, 62, 1093-102.	0.9	237
5	Organ selectivity in metastasis: regulation by chemokines and their receptors. Clinical and Experimental Metastasis, 2008, 25, 345-356.	3.3	235
6	Inflammatory mediators in breast cancer: Coordinated expression of TNFÎ± & IL-1Î² with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer, 2011, 11, 130.	2.6	229
7	Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. Journal of Leukocyte Biology, 2010, 89, 31-39.	3.3	197
8	NLRP3 inflammasome in fibroblasts links tissue damage with inflammation in breast cancer progression and metastasis. Nature Communications, 2019, 10, 4375.	12.8	190
9	Characterization of Synthetic Human Granulocyte Chemotactic Protein 2:Â Usage of Chemokine Receptors CXCR1 and CXCR2 andin VivoInflammatory Propertiesâ€. Biochemistry, 1997, 36, 2716-2723.	2.5	145
10	Differential usage of the CXC chemokine receptors 1 and 2 by interleukinâ€8, granulocyte chemotactic proteinâ€2 and epithelialâ€cellâ€derived neutrophil attractantâ€78. FEBS Journal, 1998, 255, 67-73.	0.2	133
11	The Chemokine CCL5 as a Potential Prognostic Factor Predicting Disease Progression in Stage II Breast Cancer Patients. Clinical Cancer Research, 2006, 12, 4474-4480.	7.0	131
12	The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer. Cancer Letters, 2014, 352, 36-53.	7.2	124
13	Tumor-Stroma-Inflammation Networks Promote Pro-metastatic Chemokines and Aggressiveness Characteristics in Triple-Negative Breast Cancer. Frontiers in Immunology, 2019, 10, 757.	4.8	119
14	Regulation of the inflammatory profile of stromal cells in human breast cancer: prominent roles for TNF-Î± and the NF-ÎºB pathway. Stem Cell Research and Therapy, 2015, 6, 87.	5.5	108
15	The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines. Immunology Letters, 2004, 92, 171-178.	2.5	85
16	Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: A basis for tumor-promoting interactions. Cytokine, 2008, 44, 191-200.	3.2	83
17	Beyond Cell Motility: The Expanding Roles of Chemokines and Their Receptors in Malignancy. Frontiers in Immunology, 2020, 11, 952.	4.8	82
18	DIFFERENTIAL MODES OF REGULATION OF CXC CHEMOKINE-INDUCED INTERNALIZATION AND RECYCLING OF HUMAN CXCR1 AND CXCR2. Cytokine, 1999, 11, 996-1009.	3.2	80

#	Article	IF	Citations
19	Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups. Breast Cancer Research, 2016, 18, 74.	5.0	75
20	Interleukin-8 Receptor Î². Journal of Biological Chemistry, 1995, 270, 9121-9128.	3.4	67
21	Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer. Frontiers in Immunology, 2019, 10, 804.	4.8	65
22	miRNA-1246 induces pro-inflammatory responses in mesenchymal stem/stromal cells by regulating PKA and PP2A. Oncotarget, 2017, 8, 43897-43914.	1.8	63
23	Progression of mouse mammary tumors: MCP-1-TNF? cross-regulatory pathway and clonal expression of promalignancy and antimalignancy factors. International Journal of Cancer, 2003, 106, 879-886.	5.1	62
24	GCP-2â€“induced internalization of IL-8 receptors: hierarchical relationships between GCP-2 and other ELR+-CXC chemokines and mechanisms regulating CXCR2 internalization and recycling. Blood, 2000, 95, 1551-1559.	1.4	58
25	Site-specific metastasis formation. Cell Adhesion and Migration, 2009, 3, 328-333.	2.7	55
26	The Tumor-Promoting Flow of Cells Into, Within and Out of the Tumor Site: Regulation by the Inflammatory Axis of TNFÎ± and Chemokines. Cancer Microenvironment, 2012, 5, 151-164.	3.1	55
27	Inflammatory Factors of the Tumor Microenvironment Induce Plasticity in Nontransformed Breast Epithelial Cells: EMT, Invasion, and Collapse of Normally Organized Breast Textures. Neoplasia, 2013, 15, 1330-IN5.	5.3	55
28	The angiogenic factors CXCL8 and VEGF in breast cancer: regulation by an array of pro-malignancy factors. Cancer Letters, 2005, 217, 73-86.	7.2	51
29	Actin Filaments Are Involved in the Regulation of Trafficking of Two Closely Related Chemokine Receptors, CXCR1 and CXCR2. Journal of Immunology, 2001, 166, 1272-1284.	0.8	50
30	IL-8-Induced Migratory Responses through CXCR1 and CXCR2:Â Association with Phosphorylation and Cellular Redistribution of Focal Adhesion Kinaseâ€. Biochemistry, 2003, 42, 2874-2886.	2.5	49
31	CXCL8-induced FAK phosphorylation via CXCR1 and CXCR2: Cytoskeleton- and integrin-related mechanisms converge with FAK regulatory pathways in a receptor-specific manner. Cytokine, 2006, 33, 1-16.	3.2	43
32	Inflammation-Driven Breast Tumor Cell Plasticity: Stemness/EMT, Therapy Resistance and Dormancy. Frontiers in Oncology, 2020, 10, 614468.	2.8	38
33	MCP-1 expression as a potential contributor to the high malignancy phenotype of murine mammary adenocarcinoma cells. Immunology Letters, 1999, 68, 141-146.	2.5	35
34	Chemokine axes in breast cancer: factors of the tumor microenvironment reshape the CCR7-driven metastatic spread of luminal-A breast tumors. Journal of Leukocyte Biology, 2016, 99, 1009-1025.	3.3	30
35	Co-Inflammatory Roles of TGFÎ²1 in the Presence of TNFÎ± Drive a Pro-inflammatory Fate in Mesenchymal Stem Cells. Frontiers in Immunology, 2017, 8, 479.	4.8	27
36	Epidermal Growth Factor and Estrogen Act by Independent Pathways to Additively Promote the Release of the Angiogenic Chemokine CXCL8 by Breast Tumor Cells. Neoplasia, 2011, 13, 230-243.	5.3	25

#	Article	IF	Citations
37	Persistent Inflammatory Stimulation Drives the Conversion of MSCs to Inflammatory CAFs That Promote Pro-Metastatic Characteristics in Breast Cancer Cells. Cancers, 2021, 13, 1472.	3.7	25
38	Microenvironmental networks promote tumor heterogeneity and enrich for metastatic cancer stem-like cells in Luminal-A breast tumor cells. Oncotarget, 2016, 7, 81123-81143.	1.8	23
39	Intracellular trafficking of human CXCR1 and CXCR2: regulation by receptor domains and actin-related kinases. European Journal of Immunology, 2002, 32, 3525-3535.	2.9	20
40	Mechanisms Regulating the Secretion of the Promalignancy Chemokine CCL5 by Breast Tumor Cells: CCL5's 40s Loop and Intracellular Glycosaminoglycans. Neoplasia, 2012, 14, 1-IN3.	5.3	17
41	Progression of Luminal Breast Tumors Is Promoted by MÃ©nage Ã Trois between the Inflammatory Cytokine TNFÎ±and the Hormonal and Growth-Supporting Arms of the Tumor Microenvironment. Mediators of Inflammation, 2013, 2013, 1-19.	3.0	17
42	The inflammatory cytokine TNFÎ± cooperates with Ras in elevating metastasis and turns WT-Ras to a tumor-promoting entity in MCF-7 cells. BMC Cancer, 2014, 14, 158.	2.6	16
43	Intracellular cross-talk between the GPCR CXCR1 and CXCR2: Role of carboxyl terminus phosphorylation sites. Experimental Cell Research, 2008, 314, 352-365.	2.6	12
44	Tumor Necrosis Factor Î±: Taking a Personalized Road in Cancer Therapy. Frontiers in Immunology, 2022, 13, .	4.8	12
45	Notch-Inflammation Networks in Regulation of Breast Cancer Progression. Cells, 2020, 9, 1576.	4.1	11
46	The CCL5/CCR5 Axis in Cancer. , 2009, , 109-130.		11
47	Breast Cancer: Coordinated Regulation of CCL2 Secretion by Intracellular Glycosaminoglycans and Chemokine Motifs. Neoplasia, 2014, 16, 723-740.	5.3	10
48	TNFR2+ TILs are significantly associated with improved survival in triple-negative breast cancer patients. Cancer Immunology, Immunotherapy, 2020, 69, 1315-1326.	4.2	10
49	Partners in crime: TNFÎ±-based networks promoting cancer progression. Cancer Immunology, Immunotherapy, 2020, 69, 263-273.	4.2	9
50	Tumor Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Human Breast Cancer Are Mediated by PD-L1-S283 and Chemokine Axes. Cancers, 2022, 14, 1042.	3.7	7
51	Continuous Inflammatory Stimulation Leads via Metabolic Plasticity to a Prometastatic Phenotype in Triple-Negative Breast Cancer Cells. Cells, 2021, 10, 1356.	4.1	6
52	Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ TILs in Triple-Negative Breast Tumors. Cells, 2021, 10, 1429.	4.1	5
53	Tumor-Promoting Circuits That Regulate a Cancer-Related Chemokine Cluster: Dominance of Inflammatory Mediators Over Oncogenic Alterations. Cancers, 2012, 4, 55-76.	3.7	4
54	Chapter 1 Chemokines in Human Breast Tumor Cells. Methods in Enzymology, 2009, 460, 3-16.	1.0	2

#	Article	IF	Citations
55	The Versatile World of Inflammatory Chemokines in Cancer. , 2013, , 135-175.		1